Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer

We report the first results from a phase II, open-label study designed to evaluate the efficacy and safety of bevacizumab in combination with trastuzumab and capecitabine as first-line therapy for human epidermal growth factor receptor (HER)-2-positive locally recurrent (LR) or metastatic breast can...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Martín, Miguel, Makhson, Anatoly, Gligorov, Joseph, Lichinitser, Mikhail, Lluch, Ana, Semiglazov, Vladimir, Scotto, Nana, Mitchell, Lada, Tjulandin, Sergei
Формат: Artigo
Язык:Inglês
Опубликовано: AlphaMed Press 2012
Предметы:
Academia-Pharma Intersect
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3336828/
https://ncbi.nlm.nih.gov/pubmed/22467666
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0344
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы